The Cancer Letter
Podcast Description
The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973.
With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology, providing authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health.
This weekly podcast features interviews, discussions, and more to dig deep into the issues that shape oncology.
Podcast Insights
Content Themes
Covers vital themes in oncology including cancer therapies, drug regulation, cancer research funding, and public health, with episodes discussing topics like cancer incidence rates, the impact of government policies on federal health employees, and significant scientific discoveries such as the EGFR mutation in lung cancer.
The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973.
With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology, providing authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health.
This weekly podcast features interviews, discussions, and more to dig deep into the issues that shape oncology.
Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claimed that Tempus AI Inc., an AI-driven precision and genomic testing company, had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.
“Ambry contained genetic information from a lot of people,” Paul Goldberg, editor and publisher of The Cancer Letter, said. “And the question is, were these people consented properly before the data were actually put into the kind of combined—if it was indeed combined with Tempus data—and before it was used, again, if it was indeed used for drug development?”
On this week’s episode, Paul and Jacquelyn Cobb, associate editor of The Cancer Letter, talk about last week’s breaking news regarding two lawsuits being brought against Tempus for potentially violating genetic privacy laws.
“So, it's all very interesting. It's also making a lot of people nervous,” Paul said. “I know that at cancer centers, and elsewhere, because of just the way all of this is regulated. But I think the issue that fascinated me was that you can de-identify something—maybe—but is it really de- identifiable with DNA research?”
Researchers say that “deidentified”— a word used often in the context of germline data in order to ease privacy concerns—doesn’t mean “deidentifiable.”
“It's just this interesting idea that the idea of de-identified predates our ability to sequence our entire genome,” Jacquelyn said. “The technology outpaced our regulatory frameworks.”
Stories mentioned in this podcast include:
The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
When radiology fails to fix clinical trial imaging workflow at sites…
A transcript of this podcast is available: https://cancerletter.com/podcastc/20260304-tempus/
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.